


activation of MAGL is a promising new therapeutic strategy for providing neuroprotection and myelin regeneration. Accordingly, there is a high unmet medical need for new MAGL inhibitors.


Summary of the Invention

~~In a first aspect, the~~The present ~~invention~~disclosure provides a compound of formula (I)



or a pharmaceutically acceptable salt thereof, wherein wherein A, L, X, m, n, R¹ and R² are as described herein.

In one aspect, the present disclosure provides a compound of formula (I)



or a pharmaceutically acceptable salt thereof,

wherein:

(i) X is C-R³; m is 0 or 1; n is selected from 0, 1 and 2; and L is selected from – (CH₂)_p–, –O–, –OCH₂–, –CH₂OCH₂–, –CF₂CH₂–, –CH=CH–, –(CR¹⁶R¹⁷)_q–CH₂O–, and –CH₂CF₂–; or

(ii) X is N; m is 1; n is 1 or 2; and L is –(CH₂)_p– or –CF₂CH₂–;

p is selected from 1, 2 and 3;

q is 0 or 1;

A is selected from:

(i) C₆–C₁₄–aryl substituted with R⁴, R⁵ and R⁶;

(ii) 5- to 14-membered heteroaryl substituted with R⁷, R⁸ and R⁹; and

(iii) 3- to 14-membered heterocycloalkyl substituted with R¹⁰, R¹¹ and R¹²;

R¹ is hydrogen or C₁₋₆–alkyl;

R² is selected from hydrogen, C₁₋₆–alkyl and hydroxy-C₁₋₆–alkyl;


R³ is selected from hydrogen, halogen, hydroxy, C₁₋₆-alkoxy, C₁₋₆-alkyl and halo-C₁₋₆-alkyl;

each of R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹ and R¹² is independently selected from hydrogen, halogen, cyano, hydroxy, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, hydroxy-C₁₋₆-alkyl, C₁₋₆-alkanoyl, halo-C₁₋₅-alkyl-CH(OH)-, C₁₋₆-alkoxy, halo-C₁₋₆-alkoxy, SF₅, CH₃SO₂, C₃₋₁₀-cycloalkyl, C₃₋₁₀-cycloalkyl substituted with R¹³, 3- to 14-membered heterocycloalkyl, 3- to 14-membered heterocycloalkyl substituted with R¹⁴ and R¹⁵, 5- to 14-membered heteroaryl, C₆-C₁₄-aryl, C₆-C₁₄-aryloxy, halo-C₆-C₁₄-aryl, and halo-C₆-C₁₄-aryloxy;


each of R¹³, R¹⁴, and R¹⁵ is independently selected from C₁₋₆-alkyl, C₁₋₆-alkoxy, halo-C₁₋₆-alkyl, halo-C₁₋₆-alkoxy, halogen, and hydroxy; and R¹⁶ and R¹⁷, taken together with the carbon atom to which they are attached, form a C₃₋₁₀-cycloalkyl.

~~In one aspect, the~~The present ~~invention~~disclosure provides a process of manufacturing the urea compounds of formula (I) described herein, comprising:

reacting a first amine of formula **1**, wherein R¹ is as described herein, preferably wherein R¹ is hydrogen,




with a second amine **2**, wherein A, L, m, n, X and R² are as described herein




in the presence of a base and a urea forming reagent,
to form said compound of formula (I).

In a further aspect, the present disclosure provides a process of manufacturing the compounds of formula (I) as described herein, or pharmaceutically acceptable salts thereof, comprising:

reacting a first amine of formula 1, wherein R¹ is as described herein,



5 with a second amine 2, wherein A, L, m, n, X and R² are as described herein



in the presence of a base and a urea forming reagent,
to form said compound of formula (I).

10 In a further aspect, the~~The~~ present ~~invention~~disclosure provides a compound of formula (I) as described herein, when manufactured according to the processes described herein.

In a further aspect, the~~The~~ present ~~invention~~disclosure provides a compound of formula (I) as described herein, for use as therapeutically active substance.

In a further aspect, the present disclosure provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, for use as therapeutically active substance.

15 In a further aspect, the~~The~~ present ~~invention~~disclosure provides a pharmaceutical composition comprising a compound of formula (I) as described herein and a therapeutically inert carrier.

In a further aspect, the present disclosure provides a pharmaceutical composition comprising a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier.

~~In a further aspect, the~~The present ~~invention~~disclosure provides the use of a compound of formula (I) as described herein or of a pharmaceutical composition described herein for inhibiting monoacylglycerol lipase (MAGL) in a mammal.

~~In a further aspect, the~~The present ~~invention~~disclosure provides the use of a compound of formula (I) as described herein or of a pharmaceutical composition described herein for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal.

~~In a further aspect, the~~The present ~~invention~~disclosure provides the use of a compound of formula (I) as described herein or of a pharmaceutical composition described herein for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal.

~~In a further aspect, the~~The present ~~invention~~disclosure provides a compound of formula (I) as described herein or a pharmaceutical composition described herein for use in a method of inhibiting monoacylglycerol lipase in a mammal.

~~In a further aspect, the~~The present ~~invention~~disclosure provides a compound of formula (I) as described herein or a pharmaceutical composition described herein for use in the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal.

In a further aspect, the present disclosure provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described herein for use in the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal.

~~In a further aspect, the~~The present ~~invention~~disclosure provides a compound of formula (I) as described herein or a pharmaceutical composition described herein, for use in the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal.

In a further aspect, the present disclosure provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described herein for use in the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal.

~~In a further aspect, the~~The present ~~invention~~disclosure provides the use of a compound of formula (I) as described herein for the preparation of a medicament for inhibiting monoacylglycerol lipase in a mammal.

~~In a further aspect, the~~The present ~~invention~~disclosure provides the use of a compound of formula (I) as described herein for the preparation of a medicament for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal.

5 In a further aspect, the present disclosure provides use of a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal.

~~In a further aspect, the~~The present ~~invention~~disclosure provides the use of a compound of formula (I) as described herein for the preparation of a medicament for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a
10 mammal.
15

In a further aspect, the present disclosure provides use of a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal.
20

~~In a further aspect, the~~The present ~~invention~~disclosure provides a method for inhibiting monoacylglycerol lipase in a mammal, which method comprises administering an effective
25 amount of a compound of formula (I) as described herein or of a pharmaceutical composition described herein to the mammal.

~~In a further aspect, the~~The present ~~invention~~disclosure provides a method for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal, which method comprises administering an effective amount of a compound of formula (I) as described herein or of a pharmaceutical composition described
5 herein to the mammal.

~~In a further aspect, the~~The present ~~invention~~disclosure provides a method for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy
10 induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal, which method comprises administering an effective amount of a compound of formula (I) as described herein or of a pharmaceutical composition described herein to the mammal.


Detailed Description of the Invention

Definitions

15 Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein, unless

CLAIMS

1. A compound of formula (I)



or a pharmaceutically acceptable salt thereof,

wherein:

(i) X is C-R³; m is 0 or 1; n is selected from 0, 1 and 2; and L is selected from –(CH₂)_p–, –O–, –OCH₂–, –CH₂OCH₂–, –CF₂CH₂–, –CH₂=CH₂–, –(CR¹⁶R¹⁷)_q–CH₂O–, and –CH₂CF₂–; or

(ii) X is N; m is 1; n is 1 or 2; and L is –(CH₂)_p– or –CF₂CH₂–;

p is selected from 1, 2 and 3;

q is 0 or 1;

A is selected from:

(i) C₆-C₁₄-aryl substituted with R⁴, R⁵ and R⁶;

(ii) 5- to 14-membered heteroaryl substituted with R⁷, R⁸ and R⁹; and

(iii) 3- to 14-membered heterocycloalkyl substituted with R¹⁰, R¹¹ and R¹²;

R¹ is hydrogen or C₁₋₆-alkyl;

R² is selected from hydrogen, C₁₋₆-alkyl and hydroxy-C₁₋₆-alkyl;

R³ is selected from hydrogen, halogen, hydroxy, C₁₋₆-alkoxy, C₁₋₆-alkyl and halo-C₁₋₆-alkyl;


each of R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹ and R¹² is independently selected from

hydrogen, halogen, cyano, hydroxy, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, hydroxy-C₁₋₆-alkyl, C₁₋₆-alkanoyl, halo-C₁₋₅-alkyl-CH(OH)–, C₁₋₆-alkoxy, halo-C₁₋₆-alkoxy, SF₅, CH₃SO₂, C₃₋₁₀-cycloalkyl, C₃₋₁₀-cycloalkyl substituted with R¹³, 3- to 14-membered heterocycloalkyl, 3- to 14-membered heterocycloalkyl substituted with R¹⁴ and R¹⁵, 5- to 14-membered heteroaryl, C₆-C₁₄-aryl, C₆-C₁₄-aryloxy, halo-C₆-C₁₄-aryl, and halo-C₆-C₁₄-aryloxy;

each of R¹³, R¹⁴, and R¹⁵ is independently selected from C₁₋₆-alkyl, C₁₋₆-alkoxy, halo-C₁₋₆-alkyl, halo-C₁₋₆-alkoxy, halogen, and hydroxy; and


R¹⁶ and R¹⁷, taken together with the carbon atom to which they are attached, form a C₃₋₁₀-cycloalkyl.

- ~~2. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is a compound of formula (Ia):~~



~~wherein A, L, X, m, n, R¹ and R² are as defined in claim 1.~~

- ~~3. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is a compound of formula (Ib):~~



~~wherein A, L, X, m, n, R¹ and R² are as defined in claim 1.~~

- 4.2. The compound of formula I according to ~~any one of claims 1-3~~claim 1, or a pharmaceutically acceptable salt thereof, wherein:

(i) X is C-R³; m is 0 or 1; n is selected from 0, 1 and 2; and L is selected from – (CH₂)_p–, –O–, –OCH₂–, –CF₂CH₂–, –CH₂=CH₂–, –(CR¹⁶R¹⁷)_q–CH₂O–, and –CH₂OCH₂–; or

(ii) X is N; m and n are both 1; and L is –(CH₂)_p–;

p is 1 or 2;

q is 0 or 1;

R² is hydrogen or C₁₋₆-alkyl; and

R³ is selected from hydrogen, halogen, C₁₋₆-alkyl and halo-C₁₋₆-alkyl.

- 5.3. The compound of formula I according to ~~any one of claims 1-4~~claim 2, or a pharmaceutically acceptable salt thereof, wherein:

X is C-R³;

m and n are both 0; or

m and n are both 1; and

L is selected from –(CH₂)_p–, –O–, –OCH₂– and –CH₂O–;

p is 2;

q is 0;

R² is hydrogen or C₁₋₆-alkyl; and

R³ is selected from hydrogen, halogen and C₁₋₆-alkyl.

4. The compound of formula I according to claim 3, or a pharmaceutically acceptable salt thereof, wherein:

X is C-R³;

m and n are both 0; or

m and n are both 1; and

L is selected from -(CH₂)_p-, -O-, -OCH₂- and -CH₂O-;

p is 2;

q is 0;

R² is hydrogen or methyl; and

R³ is selected from hydrogen, fluoro and methyl.

5. The compound of formula I according to any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein:

R⁴ is selected from hydrogen, halogen, hydroxy, cyano, C₁₋₆-alkyl, C₁₋₆-alkanoyl, SF₅, C₁₋₆-alkoxy, halo-C₁₋₆-alkoxy, halo-C₁₋₆-alkyl, C₃₋₁₀-cycloalkyl, 3- to 14-membered heterocyclyl, 3- to 14-membered heterocycloalkyl substituted with R¹⁴ and R¹⁵, 5- to 14-membered heteroaryl, C₆-C₁₄-aryloxy, and halo-C₆-C₁₄-aryl;

R⁵ is selected from hydrogen, cyano, halogen, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, C₁₋₆-alkoxy, 3- to 14-membered heterocycloalkyl, C₃₋₁₀-cycloalkyl, 5- to 14-membered heteroaryl, and halo-C₆-C₁₄-aryl;

R⁶ is hydrogen or halogen;

R⁷ is selected from hydrogen, C₁₋₆-alkyl, C₆-C₁₄-aryl, halo-C₆-C₁₄-aryl, halo-C₆-C₁₄-aryloxy, and halo-C₁₋₆-alkyl;

R⁸ is selected from hydrogen, halogen, C₁₋₆-alkyl, and halo-C₁₋₆-alkyl;

R⁹ is hydrogen;

R¹⁰ is halogen;

R¹¹ is halogen;

R¹² is hydrogen;

R¹⁴ is selected from C₁₋₆-alkyl, C₁₋₆-alkoxy, and halogen; and

R¹⁵ is hydrogen or halogen.

~~6. The compound of formula I according to any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein p is 1 or 2.~~

~~7. The compound of formula I according to any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein p is 2.~~

~~8. The compound of formula I according to any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein q is 0 or 1.~~

~~9. The compound of formula I according to any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein q is 0.~~

~~10.6.~~ The compound of formula I according to ~~any one of claims 1-9~~claim 5, or a pharmaceutically acceptable salt thereof, wherein A is selected from:

(i) C₆-C₁₄-aryl substituted with R⁴, R⁵ and R⁶; and

(ii) 5- to 14-membered heteroaryl substituted with R⁷, R⁸ and R⁹;

R⁴ is selected from halogen, SF₅, C₁₋₆-alkyl, C₁₋₆-alkoxy, halo-C₁₋₆-alkoxy, halo-C₁₋₆-alkyl, C₃₋₁₀-cycloalkyl, and 3- to 14-membered heterocycloalkyl;

R⁵ is selected from hydrogen, cyano, halogen, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, 3- to 14-membered heterocycloalkyl, C₃₋₁₀-cycloalkyl and halo-C₆-C₁₄-aryl;

R⁶ is hydrogen;

R⁷ is C₁₋₆-alkyl or halo-C₁₋₆-alkyl;

R⁸ is hydrogen or halo-C₁₋₆-alkyl; and

R⁹ is hydrogen.

~~11.7.~~ The compound of formula I according to ~~any one of claims 1-9~~claim 6, or a pharmaceutically acceptable salt thereof, wherein A is selected from:

(i) phenyl substituted with R⁴, R⁵ and R⁶;

(ii) oxazolyl substituted with R⁷, R⁸ and R⁹; and

(iii) pyridyl substituted with R⁷, R⁸ and R⁹;

R⁴ is selected from chloro, SF₅, methyl, methoxy, OCF₃, CF₃, cyclopropyl, and 2-azaspiro[3.3]heptan-2-yl;

R⁵ is selected from hydrogen, cyano, fluoro, chloro, methyl, CF₃, pyrrolidinyl, cyclopentyl, cyclopropyl and chlorophenyl;

R⁶ is hydrogen;

R⁷ is *tert*-butyl or CF₃;

R⁸ is hydrogen or CF₃; and

R⁹ is hydrogen.

12.8. The compound of formula I according to any one of claims 1-~~11~~7, or a pharmaceutically acceptable salt thereof, wherein R¹ is hydrogen.

~~13.— The compound of formula I according to any one of claims 1-12, or a pharmaceutically acceptable salt thereof, wherein R² is hydrogen or C₁₋₆-alkyl.~~

~~14.— The compound of formula I according to any one of claims 1-12, or a pharmaceutically acceptable salt thereof, wherein R² is hydrogen or methyl.~~

~~15.— The compound of formula I according to any one of claims 1-14, or a pharmaceutically acceptable salt thereof, wherein R³ is selected from hydrogen, halogen, C₁₋₆-alkyl and halo-C₁₋₆-alkyl.~~

~~16.— The compound of formula I according to any one of claims 1-14, or a pharmaceutically acceptable salt thereof, wherein R³ is selected from hydrogen, halogen and C₁₋₆-alkyl.~~

~~17.— The compound of formula I according to any one of claims 1-14, or a pharmaceutically acceptable salt thereof, wherein R³ is selected from hydrogen, fluoro and methyl.~~

~~18.— The compound of formula I according to any one of claims 1-17, or a pharmaceutically acceptable salt thereof, wherein R⁴ is selected from hydrogen, halogen, hydroxy, cyano, C₁₋₆-alkyl, C₁₋₆-alkanoyl, SF₅, C₁₋₆-alkoxy, halo-C₁₋₆-alkoxy, halo-C₁₋₆-alkyl, C₃₋₁₀-cycloalkyl, 3- to 14-membered heterocyclyl, 3- to 14-membered heterocycloalkyl substituted with R¹⁴ and R¹⁵, 5- to 14-membered heteroaryl, C₆-C₁₄-aryloxy, and halo-C₆-C₁₄-aryl.~~

~~19.— The compound of formula I according to any one of claims 1-17, or a pharmaceutically acceptable salt thereof, wherein R⁴ is selected from halogen, SF₅, C₁₋₆-alkyl, C₁₋₆-alkoxy, halo-C₁₋₆-alkoxy, halo-C₁₋₆-alkyl, C₃₋₁₀-cycloalkyl, and 3- to 14-membered heterocycloalkyl.~~

20. ~~The compound of formula I according to any one of claims 1-17, or a pharmaceutically acceptable salt thereof, wherein R⁴ is selected from chloro, SF₅, methyl, methoxy, OCF₃, CF₃, cyclopropyl, and 2-azaspiro[3.3]heptan-2-yl.~~
21. ~~The compound of formula I according to any one of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein R⁵ is selected from hydrogen, cyano, halogen, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, C₁₋₆-alkoxy, 3- to 14-membered heterocycloalkyl, C₃₋₁₀-cycloalkyl, 5- to 14-membered heteroaryl, and halo-C₆-C₁₄-aryl.~~
22. ~~The compound of formula I according to any one of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein R⁵ is selected from hydrogen, cyano, halogen, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, 3- to 14-membered heterocycloalkyl, C₃₋₁₀-cycloalkyl and halo-C₆-C₁₄-aryl.~~
23. ~~The compound of formula I according to any one of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein R⁵ is selected from hydrogen, cyano, fluoro, chloro, methyl, CF₃, pyrrolidinyl, cyclopentyl, cyclopropyl and chlorophenyl.~~
24. ~~The compound of formula I according to any one of claims 1-23, or a pharmaceutically acceptable salt thereof, wherein R⁶ is hydrogen or halogen.~~
25. ~~The compound of formula I according to any one of claims 1-23, or a pharmaceutically acceptable salt thereof, wherein R⁶ is hydrogen.~~
26. ~~The compound of formula I according to any one of claims 1-25, or a pharmaceutically acceptable salt thereof, wherein R⁷ is selected from hydrogen, C₁₋₆-alkyl, C₆-C₁₄-aryl, halo-C₆-C₁₄-aryl, halo-C₆-C₁₄-aryloxy, and halo-C₁₋₆-alkyl.~~
27. ~~The compound of formula I according to any one of claims 1-25, or a pharmaceutically acceptable salt thereof, wherein R⁷ is C₁₋₆-alkyl or halo-C₁₋₆-alkyl.~~
28. ~~The compound of formula I according to any one of claims 1-25, or a pharmaceutically acceptable salt thereof, wherein R⁷ is *tert* butyl or CF₃.~~
29. ~~The compound of formula I according to any one of claims 1-28, or a pharmaceutically acceptable salt thereof, wherein R⁸ is selected from hydrogen, halogen, C₁₋₆-alkyl, and halo-C₁₋₆-alkyl.~~

30. ~~The compound of formula I according to any one of claims 1-28, or a pharmaceutically acceptable salt thereof, wherein R⁸ is hydrogen or halo-C₁₋₆-alkyl.~~
31. ~~The compound of formula I according to any one of claims 1-28, or a pharmaceutically acceptable salt thereof, wherein R⁸ is hydrogen or CF₃.~~
32. ~~The compound of formula I according to any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein R⁹ is hydrogen.~~
33. ~~The compound of formula I according to any one of claims 1-32, or a pharmaceutically acceptable salt thereof, wherein R¹⁰ is halogen.~~
34. ~~The compound of formula I according to any one of claims 1-33, or a pharmaceutically acceptable salt thereof, wherein R¹¹ is halogen.~~
35. ~~The compound of formula I according to any one of claims 1-34, or a pharmaceutically acceptable salt thereof, wherein R¹² is hydrogen.~~
36. ~~The compound of formula I according to any one of claims 1-35, or a pharmaceutically acceptable salt thereof, wherein R¹⁴ is selected from C₁₋₆-alkyl, C₁₋₆-alkoxy, and halogen.~~
37. ~~The compound of formula I according to any one of claims 1-36, or a pharmaceutically acceptable salt thereof, wherein R¹⁵ is hydrogen or halogen.~~
38. ~~The compound of formula I according to any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein:~~
- ~~(i) —X is C-R³; m is 0 or 1; n is selected from 0, 1 and 2; and L is selected from—
(CH₂)_p—, O—, OCH₂—, (CR¹⁶R¹⁷)_q—CH₂O—, CH₂OCH₂—, CF₂CH₂—, and—
CH₂=CH₂—; or~~
- ~~(ii) —X is N; m and n are both 1; and L is—(CH₂)_p—;~~
- ~~p is 1 or 2;~~
- ~~q is 0 or 1;~~
- ~~A is selected from:~~
- ~~(i) —C₆-C₁₄-aryl substituted with R⁴, R⁵ and R⁶;~~
- ~~(ii) —5- to 14-membered heteroaryl substituted with R⁷, R⁸ and R⁹; and~~
- ~~(iii) —3- to 14-membered heterocycloalkyl substituted with R¹⁰, R¹¹ and R¹²;~~

R^1 is hydrogen or C_{1-6} -alkyl;

R^2 is hydrogen or C_{1-6} -alkyl;

R^3 is selected from hydrogen, halogen, C_{1-6} -alkyl and halo- C_{1-6} -alkyl;

R^4 is selected from hydrogen, halogen, cyano, SF_5 , C_{1-6} -alkyl, C_{1-6} -alkanoyl, C_{1-6} -alkoxy, halo- C_{1-6} -alkoxy, halo- C_{1-6} -alkyl, C_{3-10} -cycloalkyl, 3- to 14-membered heterocycloalkyl, 3- to 14-membered heterocycloalkyl substituted with R^{14} and R^{15} , 5- to 14-membered heteroaryl, halo- C_6 - C_{14} -aryl, and C_6 - C_{14} -aryloxy;

R^5 is selected from hydrogen, cyano, halogen, C_{1-6} -alkyl, halo- C_{1-6} -alkyl, C_{1-6} -alkoxy, 3- to 14-membered heterocycloalkyl, C_{3-10} -cycloalkyl, 5- to 14-membered heteroaryl and halo- C_6 - C_{14} -aryl;

R^6 is hydrogen or halogen;

R^7 is selected from hydrogen, C_{1-6} -alkyl, C_6 - C_{14} -aryl, halo- C_6 - C_{14} -aryl, halo- C_6 - C_{14} -aryloxy, and halo- C_{1-6} -alkyl;

R^8 is selected from hydrogen, halogen, C_{1-6} -alkyl, and halo- C_{1-6} -alkyl;

R^9 is hydrogen;

R^{10} is halogen;

R^{11} is halogen;

R^{12} is hydrogen;

R^{14} is selected from halogen, C_{1-6} -alkyl, and C_{1-6} -alkoxy;

R^{15} is hydrogen or halogen; and

R^{16} and R^{17} , taken together with the carbon atom to which they are attached, form a C_{3-10} -cycloalkyl.

39.—The compound of formula I according to any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein:

X is $C-R^3$;

m and n are both 0; or

m and n are both 1;

L is selected from $-(CH_2)_p-$, $-O-$, $-OCH_2-$ and $-CH_2O-$;

p is 1 or 2;

A is selected from:

(i) C_6 - C_{14} -aryl substituted with R^4 , R^5 and R^6 ; and

(ii) 5- to 14-membered heteroaryl substituted with R^7 , R^8 and R^9 ;

R^1 is hydrogen;

R^2 is hydrogen or C_{1-6} -alkyl;

R^3 is selected from hydrogen, halogen and C_{1-6} -alkyl;

R^4 is selected from halogen, SF_5 , C_{1-6} -alkyl, C_{1-6} -alkoxy, halo- C_{1-6} -alkoxy, halo- C_{1-6} -alkyl, C_{3-10} -cycloalkyl, and 3- to 14-membered heterocycloalkyl;

R^5 is selected from hydrogen, cyano, halogen, C_{1-6} -alkyl, halo- C_{1-6} -alkyl, 3- to 14-membered heterocycloalkyl, C_{3-10} -cycloalkyl and halo- C_6 - C_{14} -aryl;

R^6 is hydrogen;

R^7 is C_{1-6} -alkyl or halo- C_{1-6} -alkyl;

R^8 is hydrogen or halo- C_{1-6} -alkyl; and

R^9 is hydrogen.

40.—The compound of formula I according to any one of claims 1-3, wherein:

X is $C-R^3$;

m and n are both 0; or

m and n are both 1;

L is selected from $(CH_2)_p$, O, OCH_2 and CH_2O ;

p is 1 or 2;

A is selected from:

(i) —phenyl substituted with R^4 , R^5 and R^6 ;

(ii) —oxazolyl substituted with R^7 , R^8 and R^9 ; and

(iii) —pyridyl substituted with R^7 , R^8 and R^9 ;

R^1 is hydrogen;

R^2 is hydrogen or methyl;

R^3 is selected from hydrogen, fluoro and methyl;

R^4 is selected from chloro, SF_5 , methyl, methoxy, OCF_3 , CF_3 , cyclopropyl, and 2-azaspiro[3.3]heptan-2-yl;

R^5 is selected from hydrogen, cyano, fluoro, chloro, methyl, CF_3 , pyrrolidinyl, cyclopentyl, cyclopropyl and chlorophenyl;

R^6 is hydrogen;

R^7 is selected from *tert*-butyl, methyl, and CF_3 ;

R^8 is hydrogen or CF_3 ; and

R^9 is hydrogen.

41.9. A-The compound of formula (I) according to ~~any one of claims 1 to 40~~claim 1, or a pharmaceutically acceptable salt thereof, selected from: ~~the compounds disclosed in Table 1.~~

(+)-(4aR,8aS)-6-(4-((4-(tert-Butyl)thiazol-2-yl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(+)-(4aR,8aS)-6-(4-((4-(tert-Butyl)oxazol-2-yl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
rac-(4aR,8aS)-6-[4-[(4-tert-Butylthiazol-2-yl)methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
rac-(4aR,8aS)-6-(4-((4-(tert-Butyl)oxazol-2-yl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(-)-(4aS,8aR)-6-(4-((4-(tert-Butyl)thiazol-2-yl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(-)-(4aS,8aR)-6-(4-((4-(tert-Butyl)oxazol-2-yl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
rac-(4aR,8aS)-6-(4-((2-Chloro-4-fluorophenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(+)-(4aR,8aS)-6-[4-[[4-(Trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
rac-(4aR,8aS)-6-(4-((4-Chlorophenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
rac-(4aR,8aS)-6-(4-(4-Chlorobenzyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
rac-(4aR,8aS)-6-[4-[[4-(Trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(+)- or (-)-(4aR,8aS)-6-(4-(4-(Trifluoromethyl)phenoxy)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
rac-(4aR,8aS)-6-(4-(4-(Trifluoromethyl)phenoxy)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(+)-(4aS,8aS))-6-(4-(4-(Trifluoromethyl)benzyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
rac-(4aRS,8aS)-6-[4-(Phenoxymethyl)piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

rac-(4aR,8aS)-6-(4-((5,6-Dihydro-4H-cyclopenta[d]thiazol-2-yl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

rac-(4aS,8aS)-6-(4-(4-(Trifluoromethyl)benzyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

rac-(4aR,8aS)-6-(4-((3-Phenyl-1,2,4-oxadiazol-5-yl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(-)-(4aR,8aR)-6-(4-(4-(Trifluoromethyl)benzyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(-)-(4aS,8aR)-6-[4-[[4-(Trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

rac-(4aR,8aS)-6-(4-(4-(Trifluoromethyl)benzyl)piperazine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

rac-(4aR,8aS)-6-(4-(4-Chlorobenzyl)piperazine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(-)-(4aS,8aR)-6-(4-((2-Chloro-4-fluorophenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)-(4aR,8aS)-6-(4-((2-Chloro-4-fluorophenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

rac-(4aR,8aS)-6-[4-[[5-(Trifluoromethyl)-2-pyridyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-(4-((4-(Trifluoromethyl)-1H-pyrazol-1-yl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

rac-(4aR,8aS)-6-(3-((2-Fluoro-4-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(3-((2-Chloro-4-fluorobenzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(3-((2-Fluoro-4-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aS,8aR)-6-(3-((2-Fluoro-4-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(4-(4-(Trifluoromethoxy)benzyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(4-((2,4-Difluorophenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(4-(4-Chloro-3-fluorobenzyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-4-[[1-[(4aR,8aS)-3-Oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]-4-piperidyl]methyl]benzonitrile;

(+)- or (-)-(4aR,8aS)-6-(4-(4-Chlorobenzyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-[3-[4-(Trifluoromethyl)phenyl]methyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(+)- or (-)-(4aR,8aS)-6-(4-((4,4-Difluoropiperidin-1-yl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(4-((5-(tert-Butyl)oxazol-2-yl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-[4-[2-Fluoro-4-methoxyphenoxy)methyl]piperidine-1-carbonyl]hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(4-(2-Chloro-4-(trifluoromethyl)phenoxy)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aS,8aR)-6-(4-(((6-(Trifluoromethyl)pyridin-3-yl)oxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(4-(((6-(Trifluoromethyl)pyridin-3-yl)oxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(4-(3-(Trifluoromethyl)phenoxy)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aS,8aR)-6-[4-[2-Chloro-4-(trifluoromethoxy)phenoxy]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(+)- or (-)-(4aR,8aS)-6-[4-[2-Chloro-4-(trifluoromethoxy)phenoxy]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(+)- or (-)-(4aR,8aS)-6-(3-((2-Fluoro-4-(trifluoromethyl)phenoxy)methyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aS,8aR)-6-[4-[2-Chloro-4-fluoro-phenoxy)methyl]-4-methyl-piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(+)- or (-)-(4aS,8aR)-6-(4-((2,4-Difluorophenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(4-((4-Chloro-2-fluorophenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(4-((4-Fluoro-2-(trifluoromethyl)phenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(4-((2-Fluoro-4-(trifluoromethyl)phenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(4-(2-(Pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(4-((2-Chloro-4-(trifluoromethyl)phenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-2-[[1-[(4aR,8aS)-3-Oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]-4-piperidyl]methoxy]-5-fluoro-benzonitrile;

(+)- or (-)-(4aR,8aS)-6-(4-(2-(Pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(3-((2-Chloro-4-fluorophenoxy)methyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-[4-[[2-Cyclopentyl-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(+)- or (-)-3-Chloro-4-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)piperidin-4-yl)methoxy)benzonitrile;

(+)- or (-)-(4aR,8aS)-6-(4-((4-(Trifluoromethyl)-1H-imidazol-1-yl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(4-((4-Fluoro-2-methylphenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(3-((2-Chloro-4-(trifluoromethyl)phenoxy)methyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(4-((2-Chloro-4-fluorophenoxy)methyl)-4-fluoropiperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)- or (-)-(4aR,8aS)-6-(4-((4-(tert-Butyl)-1H-pyrazol-1-yl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(2R,4aR,8aS)-2-methyl-6-[4-[[4-(trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(+)- or (-)-(4aR,8aS)-6-(4-(Benzo[d]oxazol-2-ylmethyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(+)- or (-)-(4aR,8aS)-6-(4-((4',6-Dichloro-[1,1'-biphenyl]-3-yl)oxy)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(+)- or (-)-(4aR,8aS)-6-(cis-4-((2-Chloro-4-fluorophenoxy)methyl)-3-methylpiperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(+)- or (-)-(4aR,8aS)-6-(3-((2-Chloro-4-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(+)- or (-)-(4aR,8aS)-6-(3-((4-(Trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(+)- or (-)-(4aR,8aS)-6-(3-((2-Fluoro-4-(trifluoromethoxy)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(+)- or (-)-(4aR,8aS)-6-(4-((2-Chloro-4-fluorophenoxy)methyl)-4-methylpiperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(+)- or (-)-(4aR,8aS)-6-(4-(2-(1H-Pyrazol-4-yl)-4-(trifluoromethyl)benzyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(4aR,8aS)-6-[3-[(2,4-Dichlorophenyl)methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[3-[[3-Methoxy-4-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[4-[[5-Methyl-6-(trifluoromethyl)pyridin-3-yl]oxymethyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[3-[(3-Chlorophenoxy)methyl]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[3-[(2-Chlorophenoxy)methyl]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[4-[[2-Fluoro-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[3-[(2-Chlorophenyl)methoxy]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[(3-Chlorophenyl)methoxy]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[4-[[2-Cyclopropyl-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[(4-Chlorophenoxy)methyl]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[(4-Chlorophenyl)methoxy]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[4-[[2-Methyl-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[4-[[2-Chloro-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[[4-(Trifluoromethyl)phenyl]methyl]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[[3-Fluoro-5-(Trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[[2-Fluoro-6-(trifluoromethyl)phenyl]methoxymethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[2-Methyl-3-[[4-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[[3-Chloro-4-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[(2-Chloro-4-fluorophenoxy)methyl]-3-fluoroazetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[[2-Fluoro-4-(trifluoromethyl)phenyl]methoxy]-3-(trifluoromethyl)azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[[2-Fluoro-4-(trifluoromethyl)phenyl]methoxy]-3-methylazetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[[2,4-Difluoro-5-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[[2-Fluoro-5-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[[3-Fluoro-4-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[[2-Methoxy-4-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[[4-Chloro-2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[2-Methyl-3-[[4-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[4-(Trifluoromethyl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[4-[4-Chloro-3-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[4-(4-Chloro-3-cyclopropylphenoxy)piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[4-(4-Chloro-3-morpholin-4-ylphenoxy)piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[4-[2-Methyl-4-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

2-[1-[(4aR,8aS)-3-Oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]piperidin-4-yl]oxy-5-(trifluoromethyl)benzonitrile;

(4aR,8aS)-6-[4-(Oxazolo[5,4-c]pyridin-2-ylmethyl)piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[2-[2-Fluoro-6-(trifluoromethyl)phenyl]ethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[4-[(2-Chloro-4-fluorophenoxy)methyl]azepane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[4-[[4-(Trifluoromethyl)phenyl]methyl]azepane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[4-[3-Pyrazol-1-yl-5-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[4-[[2-(2,2,2-Trifluoroethoxy)-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[4-[3-(1,2,4-Triazol-1-yl)-5-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[3-[4-Chloro-3-(trifluoromethyl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[4-(4-Chloro-3-pyrazol-1-yl-phenoxy)piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-(4-(3-Morpholino-4-(trifluoromethyl)phenoxy)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(4aR,8aS)-6-[4-[4-Chloro-3-(1,2,4-triazol-1-yl)phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[4-[3-Cyclopropyl-4-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[4-[3-Pyrazol-1-yl-4-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[4-(4-Chlorophenoxy)piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[4-[[2,6-Difluoro-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[4-[4-Chloro-3-(4-chlorophenyl)-2-fluoro-phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[3-[2-Chloro-4-(trifluoromethyl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[3-[[2-Fluoro-6-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[3-[2-(2-Fluoro-4-methyl-phenyl)ethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[3-[2-[4-Methoxy-2-(trifluoromethyl)phenyl]ethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[3-[[4-Methyl-2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR, 8aS)-6-[3-[2-[2-Methoxy-6-(trifluoromethyl)phenyl]ethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[2-[4-methyl-2-(trifluoromethyl)phenyl]ethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[2-[2-Acetyl-4-(trifluoromethyl)phenyl]ethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR, 8aS)-6-[3-[2-[2-Bromo-4-(trifluoromethyl)phenyl]ethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[[6-Fluoro-4-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[[6-Fluoro-5-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[(3,4-Dichlorophenyl)methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[(2,5-Dichlorophenyl)methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[[3-(Trifluoromethoxy)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[2-Methyl-3-[[4-methyl-3-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[2-Methyl-3-[[4-methyl-3-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[2-Methyl-3-[[4-methyl-3-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[[5-(Trifluoromethyl)-2-pyridyl]oxymethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[rel-(3R,4R)-3-Methyl-4-[[5-methyl-6-(trifluoromethyl)-3-pyridyl]oxymethyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[rel-(3S,4S)-3-Methyl-4-[[5-methyl-6-(trifluoromethyl)-3-pyridyl]oxymethyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[[2-Fluoro-4-(trifluoromethyl)phenyl]methoxy]-2-methyl-azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[[4,5-bis(Trifluoromethyl)-2-pyridyl]oxymethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[[2-Fluoro-4-(trifluoromethyl)phenyl]methoxymethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[[2-Fluoro-4-(trifluoromethyl)phenyl]methoxy]-2-methyl-azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[(4-Chloro-2-phenoxy-phenyl)methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[[2-Fluoro-4-(pentafluoro-lambda6-sulfanyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[[1-(2,4-Dichlorophenyl)cyclopropyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[[6-(4-Fluorophenoxy)-4-(trifluoromethyl)-2-pyridyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[[6-(4-Fluorophenoxy)-5-(trifluoromethyl)-2-pyridyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[[4-(4-Fluorophenyl)thiazol-2-yl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[[2-Fluoro-4-(trifluoromethyl)phenyl]methoxy]-3-(trifluoromethyl)pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[rac-(2R,3S)-3-[2-Bromo-5-(trifluoromethyl)phenoxy]-2-methyl-pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[rel-(2R,3S)-3-[2-Bromo-5-(trifluoromethyl)phenoxy]-2-methyl-pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[rel-(2S,3R)-3-[2-Bromo-5-(trifluoromethyl)phenoxy]-2-methyl-pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(+)-(4aR,8aS)-6-[3-[[2,4-bis(Trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(+)-(4aR,8aS)-6-(3-((2-Methyl-3-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)-(4aR,8aS)-6-(3-((4-Methyl-2-(trifluoromethoxy)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(4aR,8aS)-6-[2-Methyl-3-[[2-methyl-4-(trifluoromethoxy)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[2-Methyl-3-[[2-methyl-3-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(+)-(4aR,8aS)-6-[4-[2-Fluoro-4-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(+)-(4aR,8aS)-6-[4-[3-Chloro-4-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(+)-(4aR,8aS)-6-[3-(4-Chloro-3-cyclopropylphenoxy)azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(+)-(4aR,8aS)-6-[4-[2-Chloro-3-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(+)-(4aR,8aS)-6-[3-(3-Bromo-2-chloro-phenoxy)azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(+)-(4aR,8aS)-6-[3-(2-Chloro-3-cyclopropyl-phenoxy)azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(+)-(4aR,8aS)-6-[3-[3-Cyclopropyl-4-(trifluoromethyl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(+)-(4aR,8aS)-6-[3-[3-Chloro-4-(trifluoromethyl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(+)-5-[[1-[(4aR,8aS)-3-Oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]-4-piperidyl]oxy]-2-(trifluoromethyl)benzonitrile;
(+)-5-[1-[(4aR,8aS)-3-Oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]azetidin-3-yl]oxy-2-(trifluoromethyl)benzonitrile;
(+)-(4aR,8aS)-6-[3-(3-Bromo-4-chlorophenoxy)azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(+)-(4aR,8aS)-6-[3-[3-(2-Azaspiro[3.3]heptan-2-yl)-4-(trifluoromethyl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(+)-(4aR,8aS)-6-[3-[3-(3-Methylazetidin-1-yl)-4-(trifluoromethyl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

- (+)-(4aR,8aS)-6-[3-[3-(3,3-Difluoroazetidin-1-yl)-4-(trifluoromethyl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (+)-(4aR,8aS)-6-[3-[3-(3-Fluoro-3-methyl-azetidin-1-yl)-4-(trifluoromethyl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (+)-(4aR,8aS)-6-[3-[3-(6,6-Difluoro-2-azaspiro[3.3]heptan-2-yl)-4-(trifluoromethyl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (+)-(4aR,8aS)-6-[3-[3-(5-oxa-2-azaspiro[3.5]nonan-2-yl)-4-(trifluoromethyl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (+)-(4aR,8aS)-6-[3-[3-(2-Azaspiro[3.3]heptan-2-yl)-2-chloro-phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (+)-(4aR,8aS)-6-[3-[2-Chloro-3-(3-methylazetidin-1-yl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (+)-(4aR,8aS)-6-[3-[2-Chloro-3-(3-fluoro-3-methyl-azetidin-1-yl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (+)-(4aR,8aS)-6-(3-(3-(3-(tert-Butoxy)azetidin-1-yl)-2-chlorophenoxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (+)-(4aR,8aS)-6-[3-[2-Chloro-3-(5-oxa-2-azaspiro[3.4]octan-2-yl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (+)-(4aR,8aS)-6-[3-[2-chloro-3-(5-oxa-2-azaspiro[3.5]nonan-2-yl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (+)-(4aR,8aS)-6-[3-[3-(2-Azaspiro[3.3]heptan-2-yl)-5-chloro-phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (+)-(4aR,8aS)-6-[3-(3-Chloro-5-pyrrolidin-1-yl-phenoxy)azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[2-[2-Fluoro-4-(trifluoromethyl)phenyl]ethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-Fluoro-2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[2,2-Difluoro-2-[4-(trifluoromethyl)phenyl]ethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[3-[3-(Trifluoromethoxy)phenyl]methyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[3-[2-Fluoro-5-(trifluoromethyl)phenoxy]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[3-[2-Chloro-5-(trifluoromethyl)phenoxy]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[(3R or 3S)-3-[2-Fluoro-5-(trifluoromethyl)phenoxy]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[(3S or 3R)-3-[2-Fluoro-5-(trifluoromethyl)phenoxy]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[3-[(E)-2-(2-fluoro-4-methyl-phenyl)vinyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-(3-((3-Fluoro-4-(trifluoromethoxy)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(4aR,8aS)-6-(3-((E)-2-Fluoro-6-(trifluoromethyl)styryl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(4aR,8aS)-6-(3-((2,3-Dimethylbenzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(4aR,8aS)-6-(3-((2,4-Dimethylbenzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(4aR,8aS)-6-(3-((2-Methyl-4-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(4aR,8aS)-6-(3-(4-Hydroxy-2-(Trifluoromethyl)phenethyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; and
(4aR,8aS)-6-[3-[4-Methyl-3-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one.

42.10. A The compound of formula (I) according to ~~any one of claims 1 to 40~~claim 1, or a pharmaceutically acceptable salt thereof, selected from:

(+)-(4aR,8aS)-6-(4-((4-(tert-Butyl)oxazol-2-yl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

- (+)-(4aR,8aS)-6-[4-[[4-(Trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (+)-(4aR,8aS)-6-(4-((2-Chloro-4-fluorophenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- rac-(4aR,8aS)-6-(3-((2-Fluoro-4-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (+)- or (-)-(4aR,8aS)-6-(3-((2-Chloro-4-fluorobenzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (+)- or (-)-(4aR,8aS)-6-(3-((2-Fluoro-4-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (+)- or (-)-(4aR,8aS)-6-(4-(4-(Trifluoromethoxy)benzyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (+)- or (-)-(4aR,8aS)-6-(4-(4-Chloro-3-fluorobenzyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (+)- or (-)-(4aR,8aS)-6-(4-(2-Chloro-4-(trifluoromethyl)phenoxy)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (+)- or (-)-(4aR,8aS)-6-(4-(3-(Trifluoromethyl)phenoxy)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (+)- or (-)-(4aR,8aS)-6-[4-[[2-Chloro-4-(trifluoromethoxy)phenoxy]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (+)- or (-)-(4aR,8aS)-6-(3-((2-Fluoro-4-(trifluoromethyl)phenoxy)methyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (+)- or (-)-(4aR,8aS)-6-(4-((4-Chloro-2-fluorophenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (+)- or (-)-(4aR,8aS)-6-(4-((4-Fluoro-2-(trifluoromethyl)phenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (+)- or (-)-(4aR,8aS)-6-(4-((2-Fluoro-4-(trifluoromethyl)phenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (+)- or (-)-(4aR,8aS)-6-(4-(2-(Pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (+)- or (-)-(4aR,8aS)-6-(4-((2-Chloro-4-(trifluoromethyl)phenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

- (+)- or (-)-(4aR,8aS)-6-[4-[[2-Cyclopentyl-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (+)- or (-)-3-Chloro-4-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)piperidin-4-yl)methoxy)benzonitrile;
- (+)- or (-)-(4aR,8aS)-6-(3-((2-Chloro-4-(trifluoromethyl)phenoxy)methyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (+)- or (-)-(4aR,8aS)-6-(4-((2-Chloro-4-fluorophenoxy)methyl)-4-fluoropiperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (+)- or (-)-(4aR,8aS)-6-(4-((4',6-Dichloro-[1,1'-biphenyl]-3-yl)oxy)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (+)- or (-)-(4aR,8aS)-6-(cis-4-((2-Chloro-4-fluorophenoxy)methyl)-3-methylpiperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (+)- or (-)-(4aR,8aS)-6-(3-((2-Chloro-4-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (+)- or (-)-(4aR,8aS)-6-(3-((2-Fluoro-4-(trifluoromethoxy)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (+)- or (-)-(4aR,8aS)-6-(4-((2-Chloro-4-fluorophenoxy)methyl)-4-methylpiperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-[3-[(2,4-Dichlorophenyl)methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[4-[[2-Fluoro-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[4-[[2-Cyclopropyl-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[[3-Chloro-4-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[[2-Fluoro-5-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[2-[2-Fluoro-6-(trifluoromethyl)phenyl]ethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-(3-(2-fluoro-4-(trifluoromethyl)phenethyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

6-(3-((2,4-bis(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(4aR,8aS)-6-[4-[3-chloro-4-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-(3-methyl-4-(((5-methyl-6-(trifluoromethyl)pyridin-3-yl)oxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(4aR,8aS)-6-(3-((3,4-dichlorobenzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(4aR,8aS)-6-(3-((2,5-dichlorobenzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

rac-(4aR,8aS)-6-(2-methyl-3-((4-methyl-3-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(4aR,8aS)-6-(3-(((4,5-bis(trifluoromethyl)pyridin-2-yl)oxy)methyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

rac-(4aR,8aS)-6-(3-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)-2-methylazetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(4aR,8aS)-6-(3-((2-fluoro-4-(pentafluoro-l6-sulfaneyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(4aR,8aS)-6-(3-((4-methyl-2-(trifluoromethoxy)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(4aR,8aS)-6-[4-[3-cyclopropyl-4-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[2-(2-fluoro-4-methyl-phenyl)ethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[2-[4-methoxy-2-(trifluoromethyl)phenyl]ethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;


(4aR,8aS)-6-[3-[3-(2-azaspiro[3.3]heptan-2-yl)-4-(trifluoromethyl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[2-[4-methyl-2-(trifluoromethyl)phenyl]ethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-(3-((4-methyl-3-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;


(4aR,8aS)-6-(3-((2-methyl-3-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
 rac-(4aR,8aS)-6-[2-methyl-3-[[2-methyl-4-(trifluoromethoxy)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
 rac-(4aR,8aS)-6-[2-methyl-3-[[2-methyl-3-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
 (4aR,8aS)-6-[3-(4-chloro-3-cyclopropylphenoxy)azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
 (4aR,8aS)-6-[4-[2-chloro-3-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
 (4aR,8aS)-6-[3-(2-chloro-3-cyclopropyl-phenoxy)azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
 (4aR,8aS)-6-[3-[3-(2-azaspiro[3.3]heptan-2-yl)-2-chloro-phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
 (4aR,8aS)-6-[3-[2-chloro-3-(5-oxa-2-azaspiro[3.5]nonan-2-yl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
 (4aR,8aS)-6-[3-[(E)-2-(2-fluoro-4-methyl-phenyl)vinyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
 (4aR,8aS)-6-(3-((E)-2-fluoro-6-(trifluoromethyl)styryl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; and
 (4aR,8aS)-6-(3-((4-methyl-3-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one.

11. The compound of formula (I) according to claim 1, which is:




or a pharmaceutically acceptable salt thereof.

12. The compound of formula (I) according to claim 1, which is:




or a pharmaceutically acceptable salt thereof.

13. The compound of formula (I) according to claim 1, which is:




or a pharmaceutically acceptable salt thereof.

14. The compound of formula (I) according to claim 1, which is:




or a pharmaceutically acceptable salt thereof.

15. The compound of formula (I) according to claim 1, which is:




or a pharmaceutically acceptable salt thereof.

16. The compound of formula (I) according to claim 1, which is:




or a pharmaceutically acceptable salt thereof.

~~43.17.~~ A process of manufacturing the compounds of formula (I) according to any one of claims 1 to ~~4216~~, or pharmaceutically acceptable salts thereof, comprising:
reacting a first amine of formula **1**, wherein R¹ is as described in any one of claims 1 to ~~4216~~,



with a second amine **2**, wherein A, L, m, n, X and R² are as described in any one of claims 1 to ~~4216~~



in the presence of a base and a urea forming reagent,
to form said compound of formula (I).

~~44.— A compound of formula (I) according to any one of claims 1 to 42, or a pharmaceutically acceptable salt thereof, when manufactured according to the process of claim 43.~~

~~45.— The compound of formula (I) according to any one of claims 1 to 42 and 44, or a pharmaceutically acceptable salt thereof, wherein said compound of formula (I) has an IC₅₀ for monoacylglycerol lipase below 10 µM.~~

~~46.18.~~ A compound of formula (I) according to any one of claims 1 to ~~42, 44 and 4516~~, or a pharmaceutically acceptable salt thereof, for use as therapeutically active substance.

~~47.19.~~ A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to ~~42, 44 and 4516~~, or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier.

~~48.— The use of a compound of formula (I) according to any one of claims 1 to 42, 44 and 45, or a pharmaceutically acceptable salt thereof, or of a pharmaceutical composition according to claim 47 for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal.~~

~~49.~~ The use of a compound of formula (I) according to any one of claims 1 to ~~42, 44 and 45~~, or a pharmaceutically acceptable salt thereof, or of a pharmaceutical composition according to claim ~~47~~ for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal.

~~50.~~20. A compound of formula (I) according to any one of claims 1 to ~~42, 44 and 45~~16, or a pharmaceutically acceptable salt thereof, or ~~of~~ a pharmaceutical composition according to claim ~~47-19~~, for use in the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal.

~~51.~~21. A compound of formula (I) according to any one of claims 1 to ~~42, 44 and 45~~16, or a pharmaceutically acceptable salt thereof, or ~~of~~ a pharmaceutical composition according to claim ~~47-19~~, for use in the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal.

~~52.~~22. ~~The use~~Use of a compound of formula (I) according to any one of claims 1 to ~~42, 44 and 45~~16, or a pharmaceutically acceptable salt thereof, ~~for in~~ the preparation of a medicament for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal.

~~53.~~23. ~~The use~~Use of a compound of formula (I) according to any one of claims 1 to ~~42, 44 and 45~~16, or a pharmaceutically acceptable salt thereof, ~~for in~~ the preparation of a medicament for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal.

54. ~~A method for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal, which method comprises administering an effective amount of a compound of formula (I) according to any one of claims 1 to 42, 44 and 45, or a pharmaceutically acceptable salt thereof, or of a pharmaceutical composition according to claim 47 to the mammal.~~
55. ~~A method for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal, which method comprises administering an effective amount of a compound of formula (I) according to any one of claims 1 to 42, 44 and 45, or a pharmaceutically acceptable salt thereof, or of a pharmaceutical composition according to claim 47 to the mammal.~~